We previously used a DNA-encoded chemical library (DEL) screen to identify novel NLRP3-binding chemical structures with strong potential for optimization to clinical candidates, specifically for the treatment of neurological diseases (Hartman et al., 2024). The gene discussed is NLRP3; the disease is nervous system disorder.